Anthera Pharmaceuticals
 | |
| Public | |
| Traded as | NASDAQ: ANTH |
| Industry | Pharmaceuticals |
| Founded | 2004 |
| Headquarters | Hayward, California, U.S. |
Key people |
Paul F. Truex (President and CEO) |
| Website | Anthera.com |
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. A-623 (Blisibimod) is Anthera’s leading drug candidate which is being developed for treatment of both systemic lupus erythematosus and IgA nephropathy.[1][2]
Product Pipeline
Blisibimod
- Blisibimod is a selective peptibody antagonist of B-cell activating factor (BAFF). BAFF is critical to the development, maintenance and survival of B-cells, but is known to be up-regulated in autoimmune diseases.[3][4][5] It is primarily expressed by macrophages, monocytes and dendritic cells.[6] Blisibimod binds to BAFF and inhibits the interaction of BAFF with its receptors.[7] Blisibimod is currently being evaluated in clinical trials in lupus and and IgA nephropathy .
Sollpura
July 2014, Anthera acquired Sollpura (Liprotamase) from Eli Lilly and Company.[8] Sollpura is an investigational pancreatic enzyme replacement therapy (PERT) that uses three biotechnology-derived digestive enzymes intended to treat patients with endocrine pancreatic insufficiency as a result of cystic fibrosis and other diseases.[9]
References
- ↑ "Overview". Anthera Pharmaceuticals,Inc. Retrieved August 11, 2014.
- ↑ "Management Team". Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals, Inc. Retrieved August 11, 2014.
- ↑ Groom, J; Kalled, SL; Cutler, AH; Olson, C; Woodcock, SA; Schneider, P; Tschopp, J; Cachero, TG; Batten, M; Wheway, J; Mauri, D; Cavill, D; Gordon, TP; Mackay, CR; Mackay, F (Jan 2002). "Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome". J Clin Invest 109 (1): 59–68. doi:10.1172/JCI14121. PMID 11781351. Retrieved August 11, 2014.
- ↑ Petri, Michelle; Stohl, William; Chatham, Winn; McCune, Joseph; Chevrier, Marc; Ryel, Jeff; Recta, Virginia; Zhong, John; Freimuth, William. "ARTHRITIS & RHEUMATISM Vol. 58, No. 8, August 2008, pp 2453–2459 DOI 10.1002/art.23678 © 2008, American College of Rheumatology Association of Plasma B Lymphocyte Stimulator Levels and Disease Activity in Systemic Lupus Erythematosus" (PDF). Deepblue. American College of Rheumatology. Retrieved August 11, 2014.
- ↑ Zhang, J; Roschke, K; Baker, KP; Wang, Z; Alarcon, GS; Fessler, BJ; Bastian, H; Kimberly, RP; Zhou, T (2001). "Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus". Journal of immunology (Baltimore, Md. : 1950) (J Immunol) 166 (1): 6–10. doi:10.4049/jimmunol.166.1.6. PMID 11123269.
- ↑ "Product Candidates". Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals, Inc. Retrieved August 11, 2014.
- ↑ Hsu, H; Khare, SD; Lee, F; Miner, K; Hu, YL; Stolina, M; Hawkins, N; Chen, Q; Ho, SY; Min, H; Xiong, F; Boone, T; Zack, DJ. "A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease". Clin Exp Rheumatol (Clinical and Experimentla Rheumatology) 30 (2): 197–201. PMID 22325420. Retrieved August 11, 2014.
- ↑ "Anthera Pharmaceuticals Announces Acquisition of Sollpura® (liprotamase) for Exocrine Pancreatic Insufficiency From Eli Lilly and Company". Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals. Retrieved August 11, 2014.
- ↑ "Anthera Pharmaceuticals Announces Acquisition of Sollpura® (liprotamase) for Exocrine Pancreatic Insufficiency From Eli Lilly and Company". Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals. Retrieved August 11, 2014.
External links
This article is issued from Wikipedia - version of the Tuesday, July 28, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.